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Mycoplasma pneumoniae–Specific IFN-g–Producing
CD41 Effector-Memory T Cells Correlate with
Pulmonary Disease
To the Editor:
Mycoplasma pneumoniae (Mp) is a major cause of community-
acquired pneumonia (CAP) in children (1). However, the
pathogenesis of Mp CAP is not well understood. Lymphocyte
responses against Mp have been reported to promote either
protection or immunopathology in mice (1, 2). In humans,
intradermal injection of Mp antigen elicited a delayed-type
hypersensitivity skin reaction in patients withMp infection (3). The
size of the delayed-type hypersensitivity skin induration, which
depends mainly on infiltrating CD41 T helper 1 (Th1) cells,
correlated with the severity of pulmonary infiltrates in those
patients (3). These observations suggest that the Mp-specific T-cell
response contributes to Mp pulmonary disease.
We showed that the measurement of specific IgM antibody-
secreting cells (ASCs) in blood discriminated patients with CAP
with Mp infection from Mp carriers suffering from CAP caused by
other pathogens (4). Using this well-diagnosed cohort, we here
investigated the Mp-specific T-cell response and its contribution to
pulmonary disease.
Children with CAP (n = 35) and healthy controls (HCs;
n = 16) aged 3–18 years from a prospective longitudinal study
(4, 5) from which peripheral blood mononuclear cells (PBMCs)
were available were included in this study. Baseline
characteristics of subjects are shown in Table E1 in the data
supplement. The study was approved by the ethics committee of
Zurich, Switzerland (no. 2016-00148). Detailed methods are
shown in the data supplement. CAP disease severity was
assessed based on chest radiograph (CXR) findings, hypoxemia
(oxygen saturation as measured by pulse oximetry ,93%)
requiring oxygen supply, and inflammatory parameters (6).
CXRs were graded with an adapted CXR severity scoring system
(7), with grades 1, 2, and 3 representing increasing severity
(Table E2 and Figure E1).
We first developed an Mp-specific IFN-g enzyme-linked
immunospot (ELISpot) assay (data supplement (5, 8)) and
demonstrated its specificity by comparing patients with Mp PCR-
positive (Mp1) CAP and Mp1 HCs (carriers), as well as patients
with Mp PCR-negative (Mp–) CAP and Mp– HCs (Figure 1A). The
ELISpot assay detected IFN-g released by PBMCs after stimulation
with Mp antigen most frequently and pronounced in patients with
Mp1 CAP (Figures 1A and 1B). This is in line with IgM ASC
ELISpot assay results, which confirmed Mp infection in those
patients with Mp1 CAP (Table E1). However, in contrast to IgM
ASCs, which were short lived (5) and mainly present during the
symptomatic stage (<20 days after onset of symptoms), the Mp-
specific IFN-g response was significantly longer lasting and also
detectable in the convalescent stage (.20 days) (P= 0.0007)
(Figure 1C).
To identify the IFN-g–producing cells, we depleted CD41 or
CD81 T cells from PBMCs of a patient withMp1 CAP (Figure E2).
Depletion of CD41 T cells reduced IFN-g spot-forming units
(SFUs) by 96% and 88% upon 24 hours and 48 hours
preincubation with Mp antigen, respectively (Figure 1D). CD8
depletion did not markedly reduce IFN-g SFUs. These findings
were corroborated by flow cytometry: only IFN-g–producing
CD41 T cells, and almost no CD81 T cells, were detected
(Figure 1E). Among these IFN-g–producing CD41 T cells, a
significant proportion coexpressed CD69 and CD40L, identifying
antigen-responsive T cells (data not shown). Importantly, the
majority of IFN-g1CD41 T cells were detected in the effector-
memory T cell (TEM) compartment (Figures 1F and E3).
Th1 cells have been reported to contribute to immune-
mediated tissue damage in other infectious diseases (9–14).
Therefore, we correlated the Mp-specific IFN-g response with
disease severity in Mp1 CAP (Table E3). The extent of pulmonary
disease reflected by increased CXR grading correlated positively
with the degree of the specific IFN-g response in symptomatic
(R= 0.49, P= 0.03) and convalescent stage (R= 0.62, P= 0.006)
(Figures 1G and 1H). Interestingly, in contrast to patients with
CXR grade 1, those with CXR grades 2 and 3 showed even an
increase in IFN-g–producing cells over time (Figure 1I). The IFN-g
response was antigen dose dependent and most pronounced for
patients with CXR grade 3 (Figures 1J and E4A). However, the
IFN-g response did not correlate with bacterial load in the upper
respiratory tract. No relation was observed between CXR grading
and bacterial load (Figure E4B) or the Mp-specific B-cell response
(Figure E5). The acute IFN-g response was also associated with
C-reactive protein levels (P= 0.009; Figure 1K) and oxygen need
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Figure 1. Mp-specific IFN-g response by CD41 T cells. (A and B) Mp-specific IFN-g SFUs per 106 PBMCs (A) and representative patterns (B) in ELISpot
assay of Mp1 CAP (n=21 of the total 25 patient samples in Table E1 [n=1 exclusively used for flow cytometry in E and F; n=3 only available at the
convalescent stage]; samples collected at median 12 days [interquartile range, 11–16] after symptom onset), Mp1 HC (carrier, n=9), Mp– CAP (n=10),
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(P= 0.06; Figure 1L). In contrast to the IFN-g response (Figure 1I),
C-reactive protein returned to normal levels in all patients at the
convalescent stage (Figure E4C).
To our knowledge, these are the first data indicating that CD4+
TEM cells form the major population of the pathogen-specific
IFN-g response in children with Mp CAP, and that the presence
of these Th1 cells in peripheral blood correlates with pulmonary
disease severity.
The IFN-g ELISpot assay is one of the most sensitive ex vivo
detection methods for pathogen-specific T cells (8). Here, we
demonstrate high specificity of the Mp-specific IFN-g ELISpot
assay in a well-diagnosed cohort of patients with CAP and healthy
controls (4, 5). Interestingly, the detection of the IFN-g response by
ELISpot assay allowed also a differentiation between Mp infection
and carriage. However, in contrast to the IgM ASC response, which
is short-lived and associated with clinical disease (5), the long-lasting
nature of the Mp-specific IFN-g response may pose a limitation to
the IFN-g ELISpot assay as diagnostic test for Mp infection.
Our findings on the Mp-specific Th1 cell response are
corroborated by previous observations in animal models suggesting
that Th1 cells contribute to inflammatory lesions in mycoplasma
pneumonia (1, 2, 15), and clinical studies in children and adults
where the IFN-g response correlated with the disease severity
and/or radiological changes in CAP associated with Mp (16–18).
Furthermore, we expand these observations by revealing
Mp-specific TEM cells as the major Th1 cell compartment
associated with more severe disease. In fact, Th1-mediated
immunopathology has been proposed to play a role in other
infectious diseases (9–14). TEM cells migrate to inflamed
peripheral tissues and display immediate effector function (19,
20). The higher INF-g response in patients with Mp CAP with
severe disease, which even increased over time despite bacterial
clearance, points to dysregulation and expansion of effector-
memory Th1 cells rather than to a more pronounced or persistent
triggering by Mp antigens.
In conclusion, these data further support the hypothesis that
host cell-mediated immunity, particularly pathogen-specific IFN-
g–producing CD41 TEM cells, is involved in the pathogenesis of
Mp CAP. Further studies are required to reveal the exact role of
these cells in Mp pulmonary disease. n
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Figure 1. (Continued). and Mp– HC (n=7) (100,000 PBMCs per well). (C) Mp-specific IgM ASC (filled symbols) or IFN-g (empty symbols) SFUs per 106
PBMCs by ELISpot assay in relation to days after onset of symptoms (n=41 Mp1 CAP patient samples; n=21 during symptomatic stage [<20 days after
onset of symptoms] and n=20 in convalescent stage [.20 days after onset of symptoms]). (D) IFN-g SFUs per 106 PBMCs (ELISpot assay) of a patient
with Mp1 CAP without depletion (gray bars) or with depletion of CD41 (black bars) and CD81 (white bars) T cells. PBMCs were preincubated for 24 hours
and 48 hours with Mp antigen. (E) Representative flow cytometry dot plots of Mp-specific CD41IFN-g1 and CD81IFN-g1 TEM cells of a patient with Mp
1
CAP at the symptomatic stage. The percentages of IFN-g1 cells are indicated. (F) IFN-g–producing memory CD41 T-cell subsets measured by flow
cytometry of patients with Mp1 CAP during symptomatic stage (<20 d, n=10; circles) and convalescent stage (.20 d, n=9; squares), and in relation to
CXR grade 1 (white symbols) and grade 2–3 (black symbols). CD41 T-cell subsets were stained with antibodies binding to CD45RA and CCR7 (TEMRA:
CD45RA1CCR7–; TCM: CD45RA
–CCR71; TEM: CD45RA
–CCR7–). There were no statistically significant differences between percentage of IFN-g1 cells
and CXR grading per subset and stage of disease. (G–I) Mp-specific IFN-g SFUs per 106 PBMCs of patients with Mp1 CAP in relation to CXR grading
(grades 1, 2, and 3 represent increasing severity) during symptomatic stage (<20 d) (n=20 of the 21 patients in A–C with acute sample and also CXR
available) (G), convalescent stage (.20 d) (n=18 of the 20 patients in C with convalescent sample and also CXR available) (H), and over time (n=16
patients with both acute and convalescent sample and also CXR available) (I). (J) Antigen dose effect on IFN-g response upon prestimulation for 24 hours
with 0.5 mg/ml, 1 mg/ml, and 2 mg/ml antigen during symptomatic stage (<20 d) from patients with CXR grade 1 (n=7), grade 2 (n=6), and grade 3 (n=4).
(K and L)Mp-specific IFN-g SFUs per 106 PBMCs of patients withMp1 CAP (n=21), preincubated with 2 mg/ml ofMp antigen for 24 hours, and assessed
on the basis of CRP levels (K) or need for oxygen supply (L) during symptomatic stage (<20 d). Horizontal lines (A, F–H, and L) or symbols (I and J) indicate
median values and whiskers extend to the first and third quartile. Statistical significance was determined by Kruskal-Wallis test with post hoc Dunn’s
multiple comparisons test (A and F–J), Mann-Whitney U test (L), or Spearman rank correlation (K). The CXR grades (1–2–3) were used as numerical values
for statistical analysis. *P,0.05, **P,0.01, ***P,0.001, and ****P,0.0001; only statistically significant differences are indicated in the graphs.
ASC=antibody-secreting cell; CAP=community-acquired pneumonia; CRP=C-reactive protein; CXR=chest radiograph; HC=healthy control;
Mp=Mycoplasma pneumoniae; PBMC=peripheral blood mononuclear cell; R10= complete RPMI; SFU= spot-forming unit; TCM= central-memory T cell;
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Lung Gene Expression Analysis Web Portal Version 3:
Lung-at-a-Glance
To the Editor:
Recent advances in single-cell omics have provided increasing insights
into the pathogenesis of human diseases, including those affecting the
lung (1–7). The density of omics data relevant to lung biology and
diseases is increasing exponentially through the work of research
consortia and individual investigators (1, 3, 8–12). Discerning the best
way to optimize the use of these rich datasets, integrate multiomics
data, extract biologically meaningful knowledge, and make that
knowledge available to the research community in a user-friendly
manner is a challenging opportunity. With support from the National
Heart, Lung, and Blood Institute (NHLBI) “LungMAP” (Lung Map)
consortium, we developed the Lung Gene Expression Analysis
(LGEA) database and web portal to facilitate access and visualization
of extensive bulk, sorted, single-cell transcriptomic and image data
from human and mouse lungs at different stages of development and
disease (13, 14). Data hosted on LGEA are primarily produced by
LungMAP research centers. We process and interpret the data and
make it available to all investigators before its publication (8). LGEA
has been widely used by researchers from more than 130 institutions
from 52 different countries and has been cited in more than 130
scientific publications. The newly updated LGEA version 3 introduces
a new featured web toolset, “lung-at-a-glance,” for exploring
and understanding complex multiomics and imaging data, providing
an interactive web interface to bridge lung anatomic ontology
classifications to lung structure, histology, and immunofluorescence
confocal images and cell type–specific gene expression.
Lung-at-a-glance consists of “region,” “cell,” and “gene,”
three interactive components all designed to provide data access with
a single click on the icons (https://research.cchmc.org/pbge/
lunggens/tools/lung_at_glance.html). We name the toolset as
Supported by U.S. National Institutes of Health grants U01HL122642,
U01HL148856, U01HL134745, and P30 DK117467 and the Chan
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